Group One Trading
PLX icon

Group One Trading’s Protalix BioTherapeutics PLX Stock Holding History

Group One Trading’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.7K Buy
+13,222
New +$32.8K ﹤0.01% 5703
2025
Q1 		– Sell
-656
Closed -$1.57K – 8199
2024
Q4 		$1.23K Buy
+656
New +$928 ﹤0.01% 6852
2022
Q2 		– Sell
-32,646
Closed -$38.2K – 8353
2022
Q1 		$35K Sell
32,646
-597,900
-95% -$548K ﹤0.01% 6375
2021
Q4 		$524K Buy
630,546
+407,993
+183% +$427K ﹤0.01% 4083
2021
Q3 		$296K Buy
222,553
+43,465
+24% +$66.1K ﹤0.01% 4763
2021
Q2 		$342K Buy
+179,088
New +$616K ﹤0.01% 4643
2021
Q1 		– Sell
-50,280
Closed -$234K – 7924
2020
Q4 		$183K Buy
+50,280
New +$180K ﹤0.01% 4117
2020
Q2 		– Sell
-5,969
Closed -$20.4K – 6089
2020
Q1 		$14K Buy
5,969
+700
+13% +$2.31K ﹤0.01% 4424
2019
Q4 		$17K Sell
5,269
-17,511
-77% -$43.1K ﹤0.01% 4420
2019
Q3 		$47K Buy
22,780
+491
+2% +$1.47K ﹤0.01% 3998
2019
Q2 		$105K Buy
22,289
+18,118
+434% +$76.5K ﹤0.01% 3312
2019
Q1 		$18K Buy
4,171
+1,810
+77% +$8.16K ﹤0.01% 4069
2018
Q4 		$7K Sell
2,361
-1,475
-38% -$7.01K ﹤0.01% 4391
2018
Q3 		$28K Buy
+3,836
New +$19.3K ﹤0.01% 4270
2016
Q4 		– Sell
-37
Closed – – 4743
2016
Q3 		$0 Hold
37
– – ﹤0.01% 4818
2016
Q2 		$0 Hold
37
– – ﹤0.01% 4874
2016
Q1 		$0 Buy
+37
New +$317 ﹤0.01% 4853
2015
Q3 		– Sell
-1,272
Closed -$20.2K – 5113
2015
Q2 		$25K Sell
1,272
-1,181
-48% -$24.5K ﹤0.01% 3930
2015
Q1 		$44K Buy
2,453
+568
+30% +$11.1K ﹤0.01% 3434
2014
Q4 		$35K Sell
1,885
-8,907
-83% -$191K ﹤0.01% 3616
2014
Q3 		$261K Sell
10,792
-4,313
-29% -$124K ﹤0.01% 2173
2014
Q2 		$551K Buy
15,105
+7,624
+102% +$308K 0.01% 1564
2014
Q1 		$343K Buy
7,481
+2,949
+65% +$138K 0.01% 1967
2013
Q4 		$176K Sell
4,532
-1,804
-28% -$76K ﹤0.01% 2548
2013
Q3 		$287K Buy
6,336
+4,048
+177% +$208K 0.01% 2070
2013
Q2 		$112K Buy
+2,288
New +$121K ﹤0.01% 2712

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Group One Trading's PLX Position: Q1 2026 in Review

Group One Trading opened a new position in Protalix BioTherapeutics (PLX) in Q1 2026: 13,222 shares worth $28.7K. The stake represents ﹤0.01% of the portfolio and ranks #5703 among its holdings. This is a return to the name: Group One Trading previously reported a position in PLX as recently as Q4 2024.

Group One Trading first reported a position in PLX in Q2 2013 and has held it in 26 quarters since. The position peaked at $551K in Q2 2014. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Group One Trading held 13,222 shares of Protalix BioTherapeutics worth $28.7K as of Q1 2026.
  • Protalix BioTherapeutics was a new Group One Trading position in Q1 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #5703 holding.
  • Group One Trading first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 26 quarters since.
  • Group One Trading's Protalix BioTherapeutics position peaked at $551K in Q2 2014.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.